Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback

Summit Therapeutics (SMMT) shares fell to a 52-week low after the FDA rejected its lung cancer treatment candidate, Ivonescimab, due to insufficient overall survival data. The stock dropped 16.47% to $11.82. The FDA cited lack of statistically significant improvement in overall survival, despite meeting the primary endpoint of progression-free survival. CEO Robert Duggan expressed disappointment but reaffirmed commitment to advancing the drug's development.

Original reporting
Published Nov 17, 2026, 2:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$SMMT
Bearish
high confidence
Mentioned
$SMMT
Relevance
9/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$SMMTBearishHigh
01

Why it matters

The FDA rejection cites absence of statistically significant overall-survival improvement and states PFS without OS improvement does not support a positive benefit-risk profile, undermining the core efficacy case for approval.

02

Market read

A direct FDA denial is a high-impact catalyst that can drive immediate repricing, liquidity risk, and changes to development strategy expectations.

03

What to watch

The article does not specify whether Summit can resubmit, pursue an appeal, or what exact next-step evidence package is planned, which could materially affect downside severity and timing.

Relevance 9/10Novelty 9/10Timing: pre-market/early session after FDA BLA rejection news and 52-week low print

Background

Summit Therapeutics’ Ivonescimab BLA was supported by a double-blind Phase 3 trial combining Ivonescimab with chemotherapy, with PFS met as the primary endpoint.

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

Summit Therapeutics shares hit a new 52-week low after the FDA rejected its Ivonescimab BLA for lack of overall-survival benefit.

Expected impact

Likely further downside pressure as investors reprice the probability of approval and the timeline for any revised development plan.

Evidence & confidence

The article states the FDA thumbed down the BLA due to no statistically significant overall-survival improvement and an unfavorable benefit-risk profile, which is typically valuation-destructive for clinical-stage biotechs.

Market effects

Reinforces heightened FDA scrutiny on overall-survival endpoints for oncology biologics, potentially pressuring similar-stage peers’ sentiment.

Primarily US biotech sentiment, with potential spillover to NASDAQ-listed small-cap healthcare names.

Limited direct global impact, but contributes to broader regulatory-risk pricing for oncology development programs.

Counterpoint

Management frames the setback as not changing the long-term opportunity for Ivonescimab, implying potential for protocol revisions, additional datasets, or alternative endpoints.

Key entities

  • Summit Therapeutics Inc.

    NASDAQ-listed biotech whose Ivonescimab BLA was rejected by the FDA.

  • FDA

    Rejected the Biologics License Application for Ivonescimab based on overall-survival evidence.

  • Ivonescimab

    Lung cancer treatment candidate evaluated in a Phase 3 trial; BLA was denied.

Related articles

$SMMTHighAI 9/10

Summit Therapeutics sinks 16% after the FDA rejects

Summit Therapeutics' stock fell 16.44% to $11.82 on Nov. 16, 2026, after the FDA rejected ivonescimab due to insufficient survival data. The company reported $613 million in net losses for the first nine months of 2026, with no product revenue. Analysts noted the rejection could impact Summit's larger lung cancer program.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$SMMTHighAI 9/10

FDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed

The FDA declined to approve Akeso's lung cancer drug ivonescimab, developed with Summit Therapeutics, due to insufficient evidence of improved survival in trials. The drug delayed cancer progression but did not meet statistical survival requirements. Summit plans further trials, and Akeso retains rights in China. AstraZeneca invested $2B in Summit for ivonescimab's development.

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.